About BrainStorm

BrainStorm Cell Therapeutics (NASDAQ:BCLI) is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig’s disease), Multiple Sclerosis (MS) and Parkinson’s Disease (PD).

Learn More

Latest News

All News

Clinical Trials

BrainStorm’s current Phase II trial is a randomized, double-blind, placebo controlled multi-center study (Massachusetts General Hospital (MGH), the University of Massachusetts (UMass) Memorial Hospital, and the Mayo Clinic) designed to evaluate the safety and efficacy of transplantation of Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors (“MSC-NTF” or NurOwn™) in 48 ALS patients.

Learn More